PMID- 24128869
OWN - NLM
STAT- MEDLINE
DCOM- 20140910
LR  - 20140212
IS  - 1473-558X (Electronic)
IS  - 0959-4965 (Linking)
VI  - 25
IP  - 4
DP  - 2014 Mar 5
TI  - Antidepressive effect of sodium valproate involving suppression of 
      corticotropin-releasing factor expression and elevation of BDNF expression in 
      rats exposed to chronic unpredicted stress.
PG  - 205-10
LID - 10.1097/WNR.0000000000000054 [doi]
AB  - Sodium valproate (VPA) is an antiepileptic drug and mood stabilizer used to treat 
      bipolar disorders. Recently, other psychiatric uses for VPA have been based on 
      its antidepressive and neuroprotective effects. In the current work, the 
      antidepressive mechanism of VPA was investigated by studying the expression of 
      brain-derived neurotrophic factor (BDNF) and hypothalamic-pituitary-adrenal axis 
      function in rats exposed to a protocol of chronic unpredicted stress (CUS). Male 
      Sprague-Dawley rats were divided into a vehicle-treated control group (no 
      CUS+vehicle), a VPA-treated control group (no CUS+VPA), a vehicle-treated model 
      group (CUS+vehicle), and a VPA-treated model group (CUS+VPA). VPA (300 mg/kg once 
      daily) was administered to rats (no CUS+VPA and CUS+VPA) by an intragastric 
      gavage, whereas the same volume of vehicle was administered to rats in the no 
      CUS+vehicle and CUS+vehicle groups. Rat behavior, serum corticosterone level, and 
      expression of BDNF in the hippocampus and corticotrophin-releasing factor in the 
      hypothalamus were determined. Compared with the CUS+vehicle rats, the CUS+VPA 
      rats showed a significant relief in depression-like behaviors and a decrease in 
      the corticosterone level and corticotropin-releasing factor expression with 
      increasing expression of BDNF. The results suggest that the antidepressive effect 
      of VPA is at least partly related to improving hypothalamic-pituitary-adrenal 
      axis function and elevating the expression of BDNF.
FAU - Qiu, Hong-Mei
AU  - Qiu HM
AD  - Key Laboratory of Biochemistry and Molecular Pharmacology, Department of 
      Pharmacology, School of Pharmacy of Chongqing Medical University, Chongqing, 
      China.
FAU - Yang, Jun-Xia
AU  - Yang JX
FAU - Liu, Dan
AU  - Liu D
FAU - Fei, Hui-Zhi
AU  - Fei HZ
FAU - Hu, Xiao-Ya
AU  - Hu XY
FAU - Zhou, Qi-Xin
AU  - Zhou QX
LA  - eng
PT  - Journal Article
PL  - England
TA  - Neuroreport
JT  - Neuroreport
JID - 9100935
RN  - 0 (Antidepressive Agents)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (RNA, Messenger)
RN  - 614OI1Z5WI (Valproic Acid)
RN  - 9015-71-8 (Corticotropin-Releasing Hormone)
RN  - W980KJ009P (Corticosterone)
SB  - IM
MH  - Animals
MH  - Antidepressive Agents/*pharmacology
MH  - Brain-Derived Neurotrophic Factor/*metabolism
MH  - Corticosterone/blood
MH  - Corticotropin-Releasing Hormone/*metabolism
MH  - Depressive Disorder/*drug therapy/*metabolism
MH  - Gene Expression/drug effects
MH  - Hippocampus/drug effects/metabolism
MH  - Hypothalamus/drug effects/metabolism
MH  - Male
MH  - Neuropsychological Tests
MH  - RNA, Messenger/metabolism
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Stress, Psychological/drug therapy/metabolism
MH  - Task Performance and Analysis
MH  - Valproic Acid/*pharmacology
EDAT- 2013/10/17 06:00
MHDA- 2014/09/11 06:00
CRDT- 2013/10/17 06:00
PHST- 2013/10/17 06:00 [entrez]
PHST- 2013/10/17 06:00 [pubmed]
PHST- 2014/09/11 06:00 [medline]
AID - 10.1097/WNR.0000000000000054 [doi]
PST - ppublish
SO  - Neuroreport. 2014 Mar 5;25(4):205-10. doi: 10.1097/WNR.0000000000000054.